ClinicalTrials.Veeva

Menu

Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients

S

Sohag University

Status

Unknown

Conditions

COVID-19

Treatments

Diagnostic Test: real time PCR

Study type

Interventional

Funder types

Other

Identifiers

NCT05201625
Soh-Med-21-11-22

Details and patient eligibility

About

Patients infected with covid-19 have a series of clinical manifestations, including fever, cough, myalgia or fatigue, dyspnea, even acute respiratory distress syndrome (ARDS), acute cardiac injury and secondary infection, and a lot of sever patients had to been admitted to the intensive care unit (ICU)

One of the hallmark of COVID 19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. besides the positive viral nucleic acid analysis and the representative pulmonary CT findings (bilateral distribution of patchy shadows and ground glass opacity), most individual patients showed the changes in several immunological and biological markers . CD177 which is one of the most clinically important neutrophil alloantigen because: i) it is a neutrophil-specific marker representative of neutrophil activation, ii) it was the most highly differentiated expressed gene in patients, and iii) the protein can be measured in the serum, making its use as a marker clinically applicable. It is expressed on neutrophils, neutrophilic metamyelocytes, and myelocytes . Given the contribution of the neutrophil activation pathway in the clustering of COVID-19 patients, neutrophil-activation features that could act as possible reliable markers of disease evolution.

Enrollment

90 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • COVID 19 hospitalized patients (diagnosed by RT-PCR)

Exclusion criteria

  • Age below 18 years and above 80.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

90 participants in 3 patient groups

control group
Active Comparator group
Description:
Healthy control group
Treatment:
Diagnostic Test: real time PCR
ICU COVID 19 patients
Active Comparator group
Description:
ICU COVID 19 patients
Treatment:
Diagnostic Test: real time PCR
non-ICU covid 19 patients
Active Comparator group
Description:
non-ICU covid 19 patients
Treatment:
Diagnostic Test: real time PCR

Trial contacts and locations

1

Loading...

Central trial contact

abeer s mohamed, professor; mai h hamed, assistant lecturer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems